Peter Heerma, EVP, CHIEF COMMERCIAL OFFICER at Travere Therapeutics, Inc. (TVTX), sold 283,189 shares at $62.05 ($17.9M) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($17.9M) by EVP, CHIEF COMMERCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.05 | 71,938 | $4.5M | 25.0% |
| 2 | $62.59 | 27,421 | $1.7M | 9.6% |
| 3 | $63.65 | 1,400 | $89K | 0.5% |
| 4 | $65.31 | 1,431 | $93K | 0.5% |
| 5 | $63.25 | 93,604 | $5.9M | 33.2% |
| 6 | $63.65 | 79,113 |
| $5.0M |
| 28.2% |
| 7 | $65.07 | 8,282 | $539K | 3.0% |
| Total | $63.06 avg | 283,189 | $17.9M | 100% |
| Filing → |
| TVTX | SELL | 2026-02-03 | $235K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $199K | — | Filing → |
| TVTX | SELL | 2025-11-04 | $196K | — | Filing → |